When a group of renowned analytical chemists and bioinformaticists founded systems biology startup Beyond Genomics last March, it was clear proteomics would play a role in the company s vision to integrate genetic, protein, and metabolite data into a computational model of how mammalian organisms function.
At a ceremony earlier this month featuring guided tours and a discussion moderated by Eric Lander, MDS Proteomics officially unveiled its new global headquarters and functional proteomics center in Toronto.
Breaking its silence on plans for its New Jersey facility, GeneProt said last week that it has purchased six Bruker Daltonics Ultraflex MALDI-TOF/TOF mass spectrometers for its new facility in North Brunswick, NJ, and an additional system for its Geneva laboratory.
The US Patent and Trademark office has awarded AxCell Biosciences US patent 6,309,820 entitled Polypeptides Having a Functional Domain of Interest and Methods of Identifying and Using Same. The patent, with 9 claims, covers the companys method for identi
As part of a massive restructuring effort to curb costs and focus on its core database and intellectual property management businesses, Incyte Genomics has cut 56 positions at its Proteome subsidiary in Beverly, Mass., ProteoMonitor learned last week.
Proteome Systems has chosen IBM to provide the hardware and middleware for its proteomics discovery platform, Proteome Systems CEO Keith Williams said last week. An official announcement of the partnership is expected on November 20, he said.
In a sequel to its recent database deal with GeneFormatics, Celera Genomics will team with London-based Inpharmatica to develop a joint product built around Inpharmatica s structural bioinformatics technology and Celera s genomic data, the companies said last week. Notably, the effort marks the first time Celera has released its entire mammalian database to a third party for processing and structure/function annotation.
A patent and licensing dispute between Biosite and Xoma has disrupted a collaboration between Large Scale Biology Corporation (LSBC) and Biosite, and threatens to derail LSBC s efforts to develop protein microarrays, company officials told ProteoMonitor last week.
As structural biology companies race ahead to obtain x-ray crystallography structures of promising drug targets, the biggest hurdle has traditionally been getting access to tunable x-ray sources at synchrotrons.
Bruker Daltonics and Biacore have agreed to jointly develop an instrument system for analyzing proteins that combines surface plasmon resonance (SPR) and mass spectrometry, the companies said last week.
For the first time in its 13 year history, the Genome Sequencing and Analysis Conference (GSAC) devoted a morning s plenary session to proteomics, which included talks by Denis Hochstrasser, co-founder of GeneProt, Scott Patterson, vice president of proteomics at Celera, and Dolores Cahill, a protein array researcher at the Max-Planck Institute of Molecular Genetics in Berlin.
As a genomics-based biotech company, Millennium Pharmaceuticals has built some of its largest collaborations to date -- with companies such as Bayer and Aventis -- on the basis of its microarray and other gene expression technologies. But in recent months the Cambridge, Mass.-based company has indicated it is expanding its efforts in proteomics to augment its drug discovery arsenal.